SCOTTSDALE, Ariz., March 08, 2007 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly-owned subsidiary of IR BioSciences Holdings, Inc. announced today that ongoing analysis of data acquired from previously performed animal efficacy studies has revealed evidence that ImmuneRegen's developmental stage product, Radilex(TM), may stimulate hematopoietic stem cells.
Studies performed at the Oak Ridge National Laboratory reveal that ImmuneRegen's potential radioprotectant product, Radilex, not only prolonged survival of animals exposed to lethal gamma irradiation, but appeared to have increased platelet concentrations in surviving animals. As the experimental protocol required these animals to be subject to repeated blood sampling as well as irradiation, saline injections were relied on for plasma volume restoration. In the face of the resulting hemodilution, compensatory hematopoietic mechanisms were nonetheless adequately stimulated to enable survival of a number of Radilex-treated, but no untreated, animals. Blood cell quantitation showed trends in the surviving animals toward neutrophil replenishment as well. ImmuneRegen has since filed a provisional patent entitled "Method to Treat Blood Cell Depletion" to provide intellectual property protection for this finding regarding Radilex.
Continuing radiation studies will be performed at both the
Translational Genomics Research Institute (TGen) and TGen Drug
Development Services (TD2, its drug development arm) and at the
Pacific Northwest National Laboratory to further explore the impact
of radiation on the hematopoietic system of Radilex-exposed
animals. ImmuneRegen's ongoing studies will be designed to examine
mechanistic indicators at both high levels of radiation where
Radilex has shown protection, as well as at lower levels. If
successful, these studies will enable Rad